Abstract The interaction between breast tumor epithelial and stromal cells is vital for initial and recurrent tumor growth. While breast cancer-associated stromal cells provide a favorable environment for proliferation and metastasis, the molecular mechanisms contributing to this process are not fully understood. Nuclear receptors (NRs) are intracellular transcription factors that directly regulate gene expression. Little is known about the status of NRs in cancer-associated stroma. Nuclear Receptor Low-Density Taqman Arrays were used to compare the gene expression profiles of all 48 NR family members in a collection of primary cultured cancer-associated fibroblasts (CAFs) obtained from estrogen receptor (ER)a positive breast cancers (n = 9) and normal breast adipose fibroblasts (NAFs) (n = 7). Thirty-three of 48 NRs were expressed in both the groups, while 11 NRs were not detected in either. Three NRs (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1 (DAX-1); estrogen-related receptor beta (ERR-b); and RAR-related orphan receptor beta (ROR-b)) were only detected in NAFs, while one NR (liver receptor homolog-1 (LRH-1)) was unique to CAFs. Of the NRs co-expressed, four were significantly down-regulated in CAFs compared with NAFs (RAR-related orphan receptor-a (ROR-a); Thyroid hormone receptor-b (TR-b); vitamin D receptor (VDR); and peroxisome proliferator-activated receptor-c (PPAR-c)). Quantitative immunohistochemistry for LRH-1, TR-b, and PPAR-c proteins in stromal fibroblasts from an independent panel of breast cancers (ER-positive (n = 15), ERnegative (n = 15), normal (n = 14)) positively correlated with mRNA expression profiles. The differentially expressed NRs identified in tumor stroma are key mediators in aromatase regulation and subsequent estrogen Kevin C. Knower and Ashwini L. Chand contributed equally to this work.
Introduction
Tumor epithelial and stromal cell interaction is vital for initial and recurrent breast cancer growth. The stromal environment, consisting of fibroblasts, endothelial, and immune cells, plays a critical function not only in normal mammary gland morphogenesis but also provides the ideal microenvironment for tumor growth (reviewed in [1, 2] ). Key initiating events in the formation of tumors include the active recruitment, by oncogenic precursor tumor cells, of stromal cell types such as endothelial cells and macrophages, all of which induce the required adaptive changes to the microenvironment [3] . While the stroma provides a scaffold for the breast, it also regulates epithelial cell function through paracrine, physical, and hormonal exchanges.
Tumor growth is supported by the adjacent stromal tissue composing mainly of fibroblasts (termed cancer-associated fibroblasts, CAFs) via production of hormones such as estrogens [4, 5] and inflammatory cytokines such as interleukin 6 (IL-6) and stromal cell-derived factor 1a (CXCL12) [6] , growth factors such as transforming growth factor b (TGFb) [7] , and the extracellular matrix remodeling enzymes such as the matrix metalloproteinases-1 and -7 [8] . CAFs behave similar to wound repair fibroblasts that increase epithelial growth through the secretion of cytokines, growth, and extracellular matrix factors [9, 10] . However, unlike wound-healing fibroblasts, CAFs remain activated not undergoing quiescence or apoptosis, as seen during wound closure [11] .
For the majority of breast cancers, tumor growth is initiated in the epithelial compartment and is confined to the ducts (ductal carcinoma in situ, DCIS), but as the ductal layer breaks down, invasion of epithelial cells occurs (invasive ductal carcinoma, IDC). During these processes, the stroma through cell-cell and cell-microenvironment interactions regulates proliferation, survival, polarity, differentiation, and invasive capacity of epithelial cells [1, 3, 9, 12] . The importance of stroma in tumor growth has been functionally demonstrated in animal models. For example, the targeted overexpression of matrix metalloproteinase 3/stromelysin-1 in the stroma promoted mammary tumorigenesis [13] , and irradiation of the mammary stroma induced tumor growth more rapidly compared with nonirradiated tissue [14] . Among the stromal cells, the fibroblasts are known to have a prominent role in tumor progression. There is a poor understanding of the gene networks and pathways mediated by the neoplastic stroma or CAFs.
Nuclear receptors (NRs) are intracellular transcription factors that directly regulate gene expression in response to endocrine hormones and/or lipophilic molecules. Together, NRs affect a wide variety of functions, including development, cholesterol homeostasis, steroidogenesis, reproductive function, and metabolism. They are also critically involved in various cancers, in particular, breast cancer [15, 16] . This is highlighted by a recent study that discriminates the prognostic value of NRs in breast cancer and identifies novel, clinically relevant, NR signatures [16] . To date, NR expression in stroma has not been specifically addressed.
At the cellular level, NRs regulate proliferation, differentiation, and apoptosis mainly via the transcriptional regulation of target gene expression and as major points of convergence of multiple signal transduction pathways. Many of the NRs act as ligand-inducible transcription factors, responding to endogenous and exogenous hormones. There is a distinct subset of NRs that do not have identifiable ligands and are termed orphan NRs. As such, these orphan NRs provide an important avenue for the discovery of novel interacting compounds, with potential impact on many disease outcomes [17, 18] . NRs such as ERa and PR are currently the most important clinical indicators of breast tumor type and stage, response to treatment, and prognosis. In addition, data from ERa and PR knockout mouse models demonstrate the functional significance, in particular, of stromal PR in normal mammary gland development [19, 20] .
The NR superfamily comprises 48 different receptors [21] . Little is known regarding the expression of the majority of these NRs in either normal breast stroma or CAFs. We therefore profiled the expression of these 48 NRs in breast CAFs obtained from nine patients with ERapositive tumors and compared these with breast adipose fibroblasts (NAFs) derived from normal control subjects. We identified four NRs to be significantly down-regulated in CAFs compared with NAFs: ROR-a, TR-b, VDR, and PPAR-c. The NRs DAX-1, ERR-b, and ROR-b were only detected in NAFs, while LRH-1 was detected only in CAFs.
Protein expression levels for LRH-1, TR-b, and PPAR-c in stromal fibroblasts were confirmed by immunohistochemistry using a larger independent panel of normal and malignant breast tissues. These results identify novel NR targets in CAFs, suggesting that these may play important roles in mediating interactions between epithelial and stromal cells within the tumor microenvironment.
Materials and methods

Patient information and cell culture
The patient sample group used for TaqMan Low-Density Arrays comprised women with ERa-positive breast tumors (n = 9) ( Table 1) . Primary CAFs were obtained from breast tissue by either centrifugation or cell-sorting methodologies as previously described [22, 23] . Clinical details of the patients, tumor type, source, and isolation method are summarized in Table 1 . As controls, NAFs (n = 7) were either obtained from adjacent nonpathological breast tissues (outlined in Table 1 ). The histological grade of each specimen was independently evaluated. Informed consent was obtained from these patients before surgery in each institution. All fibroblast cell lines, irrelevant of their source, were maintained in DMEM/F12 growth media supplemented with 15 % fetal calf serum and antibiotics as previously described [24, 25] . Validation of NAF and CAF sample groups was performed through the use of the established CAF cell marker Stromal-Derived Factor 1 (SDF1) [26] . Significant increases in SDF-1 mRNA levels were detected in CAFs compared with NAFs in line with previous findings [26, 27] (Supplementary Fig. 1 ).
For immunohistochemical studies, formalin-fixed paraffin-embedded tissue sections of breast cancer and normal breast tissues were obtained from the Australian Breast Cancer Tissue Bank (abctb.org.au) and the Victorian Cancer BioBank (viccancerbiobank.org.au). Tissue sections of normal breast tissue biopsies were obtained from the Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center. Normal tissues were from women with no known history of breast disease and were collected following reduction mammoplasty or from volunteers who donated normal breast tissue biopsies. Breast cancer cases were primary IDC, with known hormone receptor status, tumor grade, and age at diagnosis. The characteristics of the patient group are described in Table 2 . All tissues were obtained with informed consent from donors, and the use of tissues received approval from the human research ethics committees of the participating institutions.
RNA isolation and QPCR
Total RNA was isolated using the RNeasy Kit according to manufacturers' instructions (Qiagen Australia), DNAse (Ambion) treated to remove contaminating DNA. Reverse transcription of 1.5 lg of total RNA was performed using random hexamers and SuperScript III reverse transcriptase (Invitrogen). To perform quantitative real-time pCR, we used TaqMan Low-Density Array (TLDA) microfluidic cards (Applied Biosystems, Catalog no. 4379961) which contain custom-designed primers for 48 human NRs and 16 control genes. PCR was performed on the ABI 7900HT Real-Time instrument. In brief, a total of 100 ll reaction mixture, with 50 ll cDNA template (330 ng) and an equal volume of TaqMan Ò universal master mix (Applied Biosystems), was added to each line of TLDA reservoir. PCR conditions were as follows: 2 min at 50°C, 10 min at PS proportional score, IS Intensity score, TS total score a Japanese female patients at the Tohoku University Hospital and the Tohoku Kosai Hospital, CAFs isolated by collagenase digestion and centrifugation [24] b Obtained from the Victorian Cancer Biobank following cell sorting methodologies [22] . Histological grade was determined according to Robbins et al. [87] and each score represents that of tubular formation, nuclear atypia and mitosis. ER and PR immunoreactivities were evaluated according to Allred et al. [88] Breast Cancer Res Treat (2013) 
Data analysis
Data analysis and normalization to control gene expression were performed with the ABI StatMiner Software as per manufacturers' instructions and detailed methods previously published [28] . The geNorm software (Applied Biosystems) analysis was used to select the most stable endogenous controls for data normalization. The threshold cycle Ct was automatically given by SDS2.2 software package (Applied Biosystems). A Ct [ 35 was deemed as transcript not detected. Relative quantities (RQ) were determined using the equation: RQ = 2 -DDCt . Data are expressed as mean ? SD. Wilcoxon Nonparametric test was utilized for statistical analysis, and a p \ 0.05 was considered significant.
Immunohistochemistry
Immunoperoxidase staining was performed using anti-LRH-1 (NR5A2) rabbit polyclonal (Sigma-Aldrich, Castle Hill, Australia), anti-PPAR-c mouse monoclonal (Santa Cruz Biotechnology, CA, USA), and anti-TR-b mouse monoclonal (Thermo-Fisher Scientific, North Ryde, Australia) antibodies. Tissues were first heat treated under pressure in citrate buffer, as described previously [29] , to reveal epitopes. Primary antibody incubations were performed at 4°C, overnight, either in phosphate buffered saline (pH7.5) containing 0.5 % Triton X-100 (PPAR-c and TR-b) or using Ultravision polymer reagents (LRH-1) as described by the manufacturer (Thermo-Fisher Scientific). Primary antibody binding was revealed by subsequent incubation for 30 min at room temperature with biotinylated goat secondary antibodies (Dako Australia, Botany, Australia), then 1-h, room-temperature incubation with streptavidin-horseradish peroxidase conjugate (Dako Australia), followed by color development with diaminobenzidine substrate solution (Dako Australia). Stained sections were scanned using a Hamamatsu Nanozoomer digital slide scanner. Staining was scored using a threelevel intensity score and normalizing to percent positive detection as previously described [30] . Results were independently reviewed by two additional investigators who validated the original scoring result. All three observers were experienced researchers with substantial expertise in breast tissue pathology and immunohistochemistry.
Results
To assess the relative expression profiles of NRs in breast stromal cells, we utilized Low-Density Taqman Arrays that detect all 48 NR family members along with 16 internal control genes. Of the 48 NRs, 11 NRs were not detected in either group, while 36 were expressed in the groups of NAFs compared with 34 in the CAF group (Figs. 1, 2; Table 3 ). When grouped based on their subfamily classifications, both the NAF and CAFs exhibited similar NR expression profiles for endocrine (11 of 12) and adopted orphan (8 of 11) NRs. In contrast, the expression profile of orphan NRs differed between the two study groups. In the NAF samples: 17 of the total 25 orphan NRs were expressed, while in the CAF samples, 15 were detected out of the 25 orphan NRs (Table 3 ). The three orphan NRs that were exclusively detected in NAF samples included DAX-1, ERR-b, and ROR-b (Fig. 1) . Interestingly, the expression of the orphan receptor LRH-1 was detected exclusively in CAF samples (Fig. 1) . Eleven NRs were consistently not detected in either group: CAR, ER-b, ERR-c, FXR, HNF4a, PNR, ROR-c, RXR-c, SF-1, SHP, and TLX (Fig. 2) .
Thirty-three NRs were found to be expressed in both the NAF and CAF sample groups (Fig. 1) . The relative expression of these NRs detected in both the groups varied greatly, ranging from the highly expressed GR, COUP- Grade III (n) 1 1
Age, mean (range) years 60 Normal breast cohorts (n) 1 4
Premenopausal (n) 1 1
Reduction mammoplasty (n) 7
Breast biopsy (n) 4
Age, mean (range) years 38 Post-menopausal (n) 3
Breast biopsy (n) 3
Age, mean (range) years 57 (55) (56) (57) (58) Refer to ''Materials and methods'' for further description TF2, and LXR-b NRs to those at very low levels such as ER-a or HNF4-c (Fig. 2) . Despite this, variance in expression patterns of NRs between patient samples was strikingly low. As described above, we identified four orphan NRs that had a defined expression detected in only NAFs (DAX-1, ERR-b, and ROR-b) or CAFs (LRH-1). Of the 33 NRs detected in both the groups, we identified four NRs that showed significant differences in expression between groups. Significantly down-regulated in CAFs compared with NAFs were the endocrine NRs TR-b and VDR; the adopted orphan NR PPAR-c; and the orphan NR ROR-a (Fig. 3) .
With the exception of VDR and ROR-a, mRNA levels of those NRs identified as having a differential expression pattern between normal and tumor stromal cells were relatively low in comparison with the majority of NRs expressed in either group. To confirm mRNA expression profiles correlated to those of protein, quantitative immunohistochemistry was performed on three differentially expressed NRs identified by Taqman Arrays: LRH-1, TRb, and PPAR-c (Fig. 4) . A larger independent panel of IDC breast cancers was used for the analysis (ER-positive (n = 15), ER-negative (n = 15), and normal (n = 14)) ( Table 2 ). ER-negative samples were used in this instance to determine if changes in NR expression levels were related to ER-status. Immunohistochemical analysis of the NRs in stromal fibroblasts correlated to those identified at the mRNA level. In comparison with normal tissue, both the TR-b and PPAR-c stromal stainings were significantly reduced in ER-positive tumors (Fig. 4b) . Similarly, in ERnegative tumors, both the TR-b and PPAR-c levels were reduced compared with normal; however, the difference in staining was only significant for PPAR-c (Fig. 4b) .Independent of ER-status, PPAR-c stromal staining was significantly less in the tumor samples compared with normal; while close to being statistically significant (p = 0.053), TR-b levels were also reduced compared with normal tissue regardless of ER-status. Conversely, LRH-1 stromal staining was significantly elevated in both the ER-positive and ER-negative tumors: a process also independent on ER-status (Fig. 4b) .
In summary, analysis of breast stromal fibroblasts indicates a predominantly (5 out of 8) altered pattern of expression of orphan NRs between normal and tumor. Four of these orphan NRs (DAX-1, ERR-b, ROR-b, and LRH-1) are restricted to either sample group. Interestingly, four of the 33 coexpressed NRs were significantly down-regulated in CAFs; these include TR-b, VDR, PPAR-c; and ROR-a. An increase in LRH-1 was observed in CAFs compared with NAFs. This reflected the observation that although LRH-1 was detected in a subset of NAFs in most tissues, the percent positivity of LRH-1 expression in CAFs was markedly higher leading to the statistically significant difference observed. Correlation of the protein levels of LRH-1, TR-b, and PPAR-c in an independent breast cancer sample group shows consistency to NR array data. Collectively, our data suggest that differential expression of these NRs in ER-positive and ER-negative stroma adjacent to a tumor may be an important fact of tumor progression.
Discussion
CAFs form a heterogeneous population either in response to tumor heterogeneity and/or differences in origin of cell types [31] [32] [33] . This altered stromal environment that consists of fibroblasts, endothelial, and immune cells has significant impact on tumor growth. However, what gene networks and pathways contribute to transforming the preneoplastic and CAFs are poorly understood. A majority of studies characterizing CAFs have focused on alterations to ECM proteins [34] , which describe the ''activated fibroblast'' phenotype [35] , secretion of factors such as TGFB and SDF-1 [6] , and aromatase production [4, 5] . Our study is the first focused investigation into expression profiles of NR in tumor-adjacent stroma in ER-positive breast cancers.
Among the similarities, 11 NRs were consistently not detected in either NAFs or CAF samples. Of these, similar results were found for SHP, HNF4a, TLX, FXR, CAR, and SF-1 in a larger NR profiling study that used whole normal, ER-negative, and ER-positive breast tumor tissues [16] . The absence of PR, ROR-, and RXR-expressions in the breast stroma had not been previously demonstrated; however, the lack of ER-b and ERR-c expressions is in contrast to previous observations [36] [37] [38] .
Eight NRs showed differential mRNA expression profiles in normal and tumor-associated stroma. The expression of LRH-1 was only detected in CAFs, whereas the NRs DAX-1, ERR-b, and ROR-b expressions were detected exclusively in NAFs. Furthermore, we identified four NRs to be significantly down-regulated in CAFs compared with NAFs- ROR-a, TR-b, VDR, and PPAR-c. With the exception of VDR and ROR-a, the identified NRs are expressed at relatively low levels in both the sample groups. Despite this, immunohistochemical staining of breast tumor tissue confirmed that protein expression patterns of the NRs LRH-1, TR-b, and PPAR-c in tumor-associated stroma in ER-
positive and ER-negative IDCs of the breast matched the mRNA transcript data. While in the NR array data LRH-1 mRNA levels were undetectable in normal fibroblasts, immunohistochemical staining revealed LRH-1 expression in normal breast stroma (Fig. 4a) . We observed increased LRH-1 immunostaining in tumor-adjacent stroma, consistent with previous reports [39, 40] . Furthermore, we have recently shown discordance between LRH-1 transcriptional variants and protein levels in ER-positive versus ER-negative breast cancer cell lines, a mechanism mediated by differences in mRNA stability and ER-status [41] . While we have not investigated if this discordance holds true for stromal fibroblasts, it is a possibility worth pursuing in the future. The isolation and growth of CAFs and NAFs in culture may also be reflective of this discordance compared with expression patterns in tissue biopsies. LRH-1 is well described as playing a prominent role in breast cancer where it is capable of inducing tumor cell proliferation via coregulation of ER-a target genes, tumor cell migration, and invasion [39, [42] [43] [44] . As a consequence, targeting LRH-1 in the breast is an area of intense focus [45, 46] . In support of this, LRH-1 is a key mediator in the activation of the CYP19A1 gene that encodes the cytochrome P450 enzyme aromatase [39, [47] [48] [49] to increase intratumoral estrogen levels in the tumor stroma [4, 5, 40] . Targeting this process is hypothesized to inhibit estrogen production in a breast specific manner.
We also observed significantly reduced mRNA and protein levels for TR-b and PPAR-c in tumor-associated stroma compared with normal stroma. Little is known about the expression patterns of TR-b and PPAR-c in clinical biopsies, and in the tumor stroma in particular, although both NRs have clear, established roles in mammary tumor development, and the utility of their ligands as potential breast cancer treatments is of current interest [50] . The effects of a lack of functional TR-b in the development of mammary tumors are evident in an elegant in vivo model study, where a homozygous loss of function mutation of Thrb gene causing a frameshift [51] [52] [53] resulted in increased mammary gland hyperplasia and tumor incidence, in heterozygous PTEN knockout mice [54] . While in vivo deletion of Thrb gene in the stromal and epithelial compartments may provide further insight into mechanisms affected by TR-b, the study by Guigon and coworkers presents strong functional evidence in support of clinical data where several mutations in TR-b gene correlate with increased breast cancer incidence [55] .
PPAR-c has well-defined role in adipogenesis involving preadipocyte differentiation into mature adipocytes [56] , and its roles in mammary tumorigenesis are also well established. PPARc delays the in vivo progression of 7,12-dimethylbenz[a]anthracene (DMBA)-mediated breast tumors as revealed with PPARc haplo-insufficient mice [57] . In addition, in adipocyte-specific PPARc knockout mice, tumor incidence is greater than that in the control group-treated rosiglitazone [58] . Interestingly, rosiglitazone treatment reduced mammary tumor volumes by 50 %, and this may be via reduction in BRCA1 expression in mammary stromal adipocytes. In addition, clinical studies demonstrate an inverse association of PPAR-c expression with invasive breast cancer [59] and decreased tumor recurrence [60] in patients.
A well-described mechanism through which the tumorassociated stroma contributes to tumor growth is via paracrine estrogen production. The reduced expressions of RORa, TR-b, VDR, ERR-b, DAX-1, and PPAR-c and increased LRH-1 levels in CAFs all have a demonstrated net effect on stromal estrogen synthesis pathway. Adipose tumor stromal cells are the major source of local estrogen in post-menopausal women with ER-positive breast cancer [4, 5] . While LRH-1 has been shown to have a clear role in estrogen production through the up-regulation of the aromatase gene, via the cancer-associated tissue-specific promoter PII, it is also interesting to note that ROR-a, TR-b, VDR, ERR-b, and PPAR-c, identified in this study with reduced expression, have previously been shown to repress aromatase transcription. We have previously demonstrated that PPAR-c ligands inhibit PII-derived aromatase expression in breast adipose stromal cells [61] ; the TR-b ligand triiodothyronine is capable of silencing PII-derived aromatase activity in mouse Sertoli cells [62] ; calcitriol induces VDR binding and repression of PII-mediated expression and subsequent estrogen synthesis in vitro [63] and in vivo [64] ; and finally, DAX-1 is known to antagonize aromatase expression in a number of instances [65] [66] [67] [68] . Given the importance of aromatase expression in the breast tumor stroma, our findings reveal a pattern of NR expression that fits with a sustained and increased local estrogen microenvironment. The precise mechanism of the action of these NRs on aromatase in the breast stroma warrants further investigation. We have identified a distinct set of NRs that may have an important contribution in causing the alterations in the stromal environment in response to a tumor and/or establishing the preneoplastic niche for tumor initiation. These NRs have been demonstrated to have roles in mammary development and tumorigenesis. The combined effect of reduced expression of these NRs may result in significant alterations to the tumor stromal environment via various cellular mechanisms some of which are discussed.
The reduced expressions of orphan NR ROR-a and related ROR-b may contribute to breast tumor growth via the regulation of inflammatory pathways. ROR-a is a negative regulator of inflammation, suppressing TNFainduced expressions of COX-2, IL-6, and IL-8 via the inhibition of the NF-jB promoter [69] , thereby suppressing tumor metastasis [70] . Moretti et al. [71] demonstrate that the activation of ROR-a with a selective ligand (CGP 52608) decreases tumor cell proliferation, migration, and invasion, suggesting that the activation of ROR-a may also be of therapeutic benefit in breast cancers targeting tumor growth [72] .
VDR has known roles in the suppression of cancer cell invasion, angiogenesis, and metastasis [73] [74] [75] . Indeed, VDR has important functions in regulating normal mammary development; in Vdr knockout female mice, there is more extensive ductal elongation and branching compared with wild-type, and increased responsiveness to estrogen and progesterone, represented by increases in ductal epithelial cell proliferation [76] . In the context of our observations, the decrease in VDR expression in the adjacent tissue may thus be a tumor-initiating event whereby the surrounding tissue is more responsive to hormones and for hyperplastic growth of ductal epithelial cells.
The ERRs are highly homologous in structure and functionality [77] . Their primary role is the regulation of cellular metabolism and regulation of the glycolytic pathway, the tricarboxylic acid cycle, and oxidative phosphorylation (reviewed in [78] ). This function is particularly relevant in rapidly proliferating cells such as breast tumor cells [79, 80] . While most of these functions are assigned to ERR-a and ERR-c, specifically ERR-b has been shown to regulate pluripotency in embryonic stem cells and function as a reprogramming factor for the generation of induced pluripotent cells [81] [82] [83] . The loss of expression of ERR-b expression in CAFs may thus signify a distinct change in cell reprogramming.
The orphan NR DAX-1 is found to be expressed in NAF but not in CAF samples. DAX-1 is unique in that it lacks a DNA binding motif; however, it heterodimerizes with many members of the NR superfamily to inhibit their activity. Hence, a relatively small change in DAX-1 expression may potentially have a profound effect on NR function. Highly expressed in gonadal tissue, knockout of Dax-1 gene in mice results in spermatogenic failure, while in humans, abnormalities in DAX-1 genes can lead maleto-female sex reversal [84] . Its roles in cancer have not been fully studied. DAX-1 interacts with the NR5A subfamily of orphan NRs (LRH-1 and SF-1) in several tissues to repress aromatase transcription [65-68, 85, 86] . Hence, its repression may also contribute to the overall increase in aromatase expression in CAFs.
In conclusion, we provide a cell-specific NR signature in the cancer microenvironment that may individually or collectively impact tumor proliferation and metastasis. The interrelationships between NRs and their interactions with coregulator proteins make them a complex network of transcription factors with wide-ranging cellular functions. With this in mind, we suggest that further studies should profile stromal cell characteristics adjacent to the tumor where correlations to steroid receptor status, grade, and stage will aid in the development of early prognostic markers.
